quinoxalines has been researched along with gdc-0068 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowen, JP; Güner, OF; Matesic, DF; Uko, NE | 1 |
| Hu, C; Hu, X; Shang, X; Zhao, Y; Zheng, T | 1 |
1 review(s) available for quinoxalines and gdc-0068
| Article | Year |
|---|---|
Akt Pathway Inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Diamines; Drug Design; Heterocyclic Compounds, 3-Ring; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phospholipids; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Thiadiazoles; Thiophenes | 2020 |
1 other study(ies) available for quinoxalines and gdc-0068
| Article | Year |
|---|---|
Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
Topics: Apoptosis; Bcl-2-Like Protein 11; Humans; Mitochondria; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinoxalines; Receptors, Fibroblast Growth Factor; Up-Regulation; Urinary Bladder Neoplasms | 2022 |